Several biosimilar etanercept products are now approved in the United States and in Europe, and several more “intended copy” versions are approved in poorly regulated countries. Availability of an international reference standard would allow qualification of assays for determining biological activity of intended copies or biosimilars.
Etanercept, a recombinant human tumor necrosis factor (TNF)—receptor Fc fusion protein, is an effective treatment for adults with rheumatoid arthritis, anklylosing spondylitis, psoriatic arthritis, or plaque psoriasis, and for children with juvenile idiopathic arthritis and plaque psoriasis. Patent expiration for the reference product (Enbrel) in Europe and intense development of etanercept biosimilars worldwide triggered the need for the development of an international reference standard to allow the determination of biological activity.
Several biosimilar etanercept products are now approved in the United States and in Europe, and several more “intended copy” versions of etanercept are approved in poorly regulated countries. Availability of an international reference standard (IS) would allow qualification of assays for determining biological activity of intended copies or biosimilars, enabling market availability of etanercept products with similar biological activities and ensuring patient access to products that are consistent in quality and efficacy.
Meenu Wadhwa, PhD, and colleagues sought to select a suitable standard and assign a unitage for in vitro biological activity. The researchers evaluated, in collaboration with the European Pharmacopeia, 3 candidate etanercept preparations for their suitability to serve as an IS for bioactivity of etanercept in a multicenter, international study comprising 28 laboratories from 15 countries. Their report is published in the August 2017 issue of the Journal of Immunological Methods.
The study had 2 goals: first, to assess the suitability of candidate preparations of etanercept to serve as the first IS for the bioassay of human etanercept by assaying their biological activity in a range of routine, in-house bioassays, and second, to assess the relative activity of the candidate preparations in different assays in current use and determine, if possible, concentrations of etanercept required to neutralize specific amounts of tumor necrosis factor-alpha.
The 3 preparations (coded as 13/192, 13/204, and 13/260) were tested for neutralization activity against the third TNF-alpha IS in different in vitro cell-based assays. Regardless of the assay and the amount of TNF-alpha IS used, potency estimates for the different preparations were very similar, the authors found. Results indicated that the candidate coded 13/204 was stable and suitable to serve as an IS for the biological activity of etanercept. Therefore, preparation 13/204 was established by the World Health Organization (WHO) Expert Committee on Biological Standardization in 2015 as WHO’s first IS for etanercept with an assigned in vitro bioactivity of 10,000 IU per ampule.
This first-in-class IS is available from the National Institute for Biological Standards and Control and also as a biological reference preparation from the European Directorate for the Quality of Medicines and Healthcare. It is intended to control the performance of biological assays for etanercept and to support the establishment of in-house bioassay standards, the researchers said. They stress that it is not intended for describing the labelling or dosage of etanercept therapeutic products or for use as a comparator (reference product) for biosimilarity determination.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.